dc.contributor.author | Song, Jimmy Y. | |
dc.contributor.author | Griffin, J. Daniel | |
dc.contributor.author | Larson, Nicholas R. | |
dc.contributor.author | Christopher, Matthew A. | |
dc.contributor.author | Middaugh, C. Russell | |
dc.contributor.author | Berkland, Cory J. | |
dc.date.accessioned | 2022-01-10T21:10:10Z | |
dc.date.available | 2022-01-10T21:10:10Z | |
dc.date.issued | 2021-01-18 | |
dc.identifier.citation | Song JY, Griffin JD, Larson NR, Christopher MA, Middaugh CR and Berkland CJ (2021) Synthetic Cationic Autoantigen Mimics Glatiramer Acetate Persistence at the Site of Injection and Is Efficacious Against Experimental Autoimmune Encephalomyelitis. Front. Immunol. 11:603029. doi: 10.3389/fimmu.2020.603029 | en_US |
dc.identifier.uri | http://hdl.handle.net/1808/32384 | |
dc.description.abstract | A synthetic peptide, K-PLP, consisting of 11-unit poly-lysine (K11) linked via polyethylene glycol (PEG) to proteolipid protein epitope (PLP) was synthesized, characterized, and evaluated for efficacy in ameliorating experimental autoimmune encephalomyelitis (EAE) induced by PLP. K-PLP was designed to mimic the cationic nature of the relapsing-remitting multiple sclerosis treatment, glatiramer acetate (GA). With a pI of ~10, GA is able to form visible aggregates at the site of injection via electrostatic interactions with the anionic extracellular matrix. Aggregation further facilitates the retention of GA at the site of injection and draining lymph nodes, which may contribute to its mechanism of action. K-PLP with a pI of ~11, was found to form visible aggregates in the presence of glycosaminoglycans and persist at the injection site and draining lymph nodes in vivo, similar to GA. Additionally, EAE mice treated with K-PLP showed significant inhibition of clinical symptoms compared to free poly-lysine and to PLP, which are the components of K-PLP. The ability of the poly-lysine motif to retain PLP at the injection site, which increased the local exposure of PLP to immune cells may be an important factor affecting drug efficacy. | en_US |
dc.publisher | Frontiers Media | en_US |
dc.rights | Copyright © 2021 Song, Griffin, Larson, Christopher, Middaugh and Berkland. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY). | en_US |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | en_US |
dc.subject | EAE | en_US |
dc.subject | Poly-lysine | en_US |
dc.subject | Multiple sclerosis | en_US |
dc.subject | Copaxone® | en_US |
dc.subject | Glatiramer acetate | en_US |
dc.subject | SC injection simulation | en_US |
dc.title | Synthetic Cationic Autoantigen Mimics Glatiramer Acetate Persistence at the Site of Injection and Is Efficacious Against Experimental Autoimmune Encephalomyelitis | en_US |
dc.type | Article | en_US |
kusw.kuauthor | Song, Jimmy Y. | |
kusw.kuauthor | Griffin, J. Daniel | |
kusw.kuauthor | Larson, Nicholas R. | |
kusw.kuauthor | Christopher, Matthew A. | |
kusw.kuauthor | Middaugh, C. Russell | |
kusw.kuauthor | Berkland, Cory J. | |
kusw.kudepartment | Pharmaceutical Chemistry | en_US |
kusw.kudepartment | Bioengineering | en_US |
kusw.kudepartment | Chemical and Petroleum Engineering | en_US |
dc.identifier.doi | 10.3389/fimmu.2020.603029 | en_US |
kusw.oaversion | Scholarly/refereed, publisher version | en_US |
kusw.oapolicy | This item meets KU Open Access policy criteria. | en_US |
dc.identifier.pmid | PMC7848024 | en_US |
dc.rights.accessrights | openAccess | en_US |